Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy

Bone Marrow Transplantation

Volumn 26, Issue 8, 2000, Pages 859-864

  Schimmer, A D ^a   Jamal, S ^a   Messner, H ^a   Keating, A ^a   Meharchand, J ^a   Huebsch, L ^b   Walker, I ^c   Benger, A ^c   Gluck, S ^d   Smith, A ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Northeastern Regional Cancer Centre   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Allotransplant; Autotransplant; Non Hodgkin's lymphoma

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033752610     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702625     Document Type: Article

References (14)

1. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma
3. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
4. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation
5. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy
6. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
7. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
8. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European bone marrow transplant group registry data
9. Prospective comparative trial of autologous versus allogeneic bone marrow row transplantation in patients with non-Hodgkin's lymphoma
10. Nonparametric estimation from incomplete observations
11. Regression models and life tables
12. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: A value of augmented preparative regimens - A southwest oncology group trial
13. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors
14. Evidence of a graft-versus lymphoma effect associated with allogeneic bone marrow transplantation